The RET-targeted anticancer therapy ‘Retevmo’ will reattempt reimbursement listing in Korea.

According to industry sources, Lilly Korea’s Retevmo (selpercatinib) will be deliberated by the Health Insurance Review and Assessment Service’s Cancer Disease Review Committee (CDRC) tomorrow on November 2nd.

Retevmo received marketing authorization in March this year and was deliberated by CDDC for reimbursement in May. After deliberation, the CDDC decided not to set reimbursement standards for the drug. Whether a different conclusion will be made this time remains to be seen.

The CDDC’s review process was raised as an issue at the recent NA Audit. Rep. Gi-Yoon Kang of the